insights_auto
Prečo akcie NTLA klesli 2,87%?
Preskúmať podrobnejšiechevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
12,70 USD
arrow_downward
-2,87%(-0,38) 1 d.
12. 10., 13:33:10 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre NTLA…
Otvoriť
13,08 USD
Vysoká
13,23 USD
Nízka
12,59 USD
Trh. kap.
1,78 mld.
Priem. obj.
4,94 mil.
Objem
2,21 mil.
Max. za 52 týž.
28,25 USD
Min. za 52 týž.
7,95 USD
Výnosy na akciu
-3,36 USD
Beta
1,80
Akcie v obehu
140,13 mil.
Počet zamestnancov
377
Otvoriť
13,08 USD
Vysoká
13,23 USD
Nízka
12,59 USD
Trh. kap.
1,78 mld.
Priem. obj.
4,94 mil.
Objem
2,21 mil.
Max. za 52 týž.
28,25 USD
Min. za 52 týž.
7,95 USD
Výnosy na akciu
-3,36 USD
Beta
1,80
Akcie v obehu
140,13 mil.
Počet zamestnancov
377
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Informácie o subjekte Intellia Therapeutics Inc
Generálny riaditeľJohn Leonard
Zamestnanci377
Dátum založenia2014
Hlavné sídloCambridge, Massachusetts, Spojené štáty americké
Odvetvie-